7 completed. 7 Phase 2, 3 Phase 3, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 7 | Completed 7 |
| Phase 3 | 3 | Completed 3 |
| Phase 1 | 1 | Completed 1 |
Follow Prevention: new trials by email Literature Review of Prevention trials Research Report on Prevention
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Optimizing PrEP Regimens for Pregnant Women in Sub-Saharan Africa (O-PrEP Study) - Stage 1 FTC/TDF 200mg/300mg, FTC/TDF 300mg/450mg, FTC/TDF 400mg/600mg - HIV, Prevention | Phase 2 | Completed | University of North Carolina, Chapel Hill | 54 | 2024-06-18 | 2026-02-17 |
| Abatacept s.c. for aGVHD Prevention in Haplo-HCT Abatacept s.c. - Abatacept, Acute-graft-versus-host Disease | Phase 1 / Phase 2 | Completed | The First Affiliated Hospital of Soochow University | 29 | 2021-06-01 | 2026-06-11 |
| Rivaroxaban Plus ASA in Embolic Stroke of Undetermined Source(AREST-ESUS) Rivaroxaban 2.5 Mg Oral Tablet, Rivaroxaban placebo tablets - Stroke, Prevention | Phase 2 / Phase 3 | Completed | Mazandaran University of Medical Sciences | 42 | 2020-08-22 | 2023-10-19 |
| Familias Unidas: Preventing Substance Abuse in Hispanic Youth Familias Unidas - Prevention, Family Function | Phase 2 / Phase 3 | Completed | University of Miami | 746 | 2010-08-01 | 2015-06-03 |
| Safety and Immunogenicity of an Inactivated Pandemic Influenza Vaccine pandemic influenza vaccine (H5N1 strain NIBRG-14) - Pandemic Influenza, Prevention | Phase 2 | Completed | Sinovac Biotech Co., Ltd | 402 | 2007-09-01 | 2007-11-09 |
| Parent Education for Young Teen Females parent education - Prevention | Phase 2 / Phase 3 | Completed | Education Development Center, Inc. | 500 | 2003-09-01 | 2012-07-03 |
| ODiXahip - a Phase IIa Dose Escalating Proof of Principle Trial Rivaroxaban (BAY59-7939), Enoxaparin - Thromboembolism, Prevention | Phase 2 | Completed | Bayer | 641 | 2002-12-01 | 2014-12-17 |
Sexual Behavior (1) · Smoking (1) · Stroke (1) · Substance-Related Disorders (1) · Thromboembolism (1)
Cardiovascular Diseases (2) · Vascular Diseases (2) · Behavior (1) · Brain Diseases (1) · Central Nervous System Diseases (1) · Cerebrovascular Disorders (1) · Chemically-Induced Disorders (1) · Embolism and Thrombosis (1) · Mental Disorders (1) · Nervous System Diseases (1)
Rivaroxaban (2) · Enoxaparin (1)
Bayer (1) · Education Development Center, Inc. (1) · Mazandaran University of Medical Sciences (1) · Sinovac Biotech Co., Ltd (1) · The First Affiliated Hospital of Soochow University (1) · University of Miami (1) · University of North Carolina, Chapel Hill (1)
United States (2) · Austria (1) · Belgium (1) · China (1) · Denmark (1) · France (1) · Germany (1) · Iran (1) · Israel (1) · Malawi (1) · Netherlands (1) · Norway (1) · Poland (1) · Sweden (1) · United Kingdom (1)
Athena Sharifi-Razvi (1) · Benjamin Chi, MD, MSc (1) · Guillermo Prado, PhD (1) · Jiang Wu (1) · Lynda Stranix-Chibanda, MBChB, MMed (1) · Monireh Ghazaeian (1) · Peter Anderson, PharmD (1)
PMID 19281330, PMID 28207330, PMID 30514652, PMID 40037214
R01AA014515 (1), R01AI157859 (1)